89Zr-bevacizumab

DRUG4 trials

Sponsors

Leids Universitair Medisch Centrum (LUMC), University Medical Center Groningen, Dana-Farber Cancer Institute

Conditions

Inflammatory Breast CarcinomaMultiple MyelomaNF2-related schwannomatosisNeuroendocrine Tumors

Early Phase 1

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

CompletedNCT01894451

Dana-Farber Cancer InstituteInflammatory Breast Carcinoma

Start: 2015-06-30End: 2017-03-17Updated: 2019-12-12

Phase 2

(NFPET) ‘89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2

Not yet recruitingCTIS2024-512860-75-00

Leids Universitair Medisch Centrum (LUMC)NF2-related schwannomatosis

Target: 24Updated: 2024-10-01

Unknown Phase

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

CompletedNCT01338090

University Medical Center GroningenNeuroendocrine Tumors

Start: 2010-04-30End: 2012-03-31Updated: 2012-04-03

89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

University Medical Center GroningenMultiple Myeloma

Start: 2013-05-31Target: 20Updated: 2013-05-21

Related Papers

Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy

Cancer Research2017-02-15